Evidence map›Paper›PMID 33357491›Full record

Trial reportThe lancet. Diabetes & endocrinology2021

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.

Stuart J McGurnaghan, Amanda Weir, Jen Bishop, Sharon Kennedy, Luke A K Blackbourn, David A McAllister, Sharon Hutchinson, Thomas M Caparrotta, Joseph Mellor, Anita Jeyam and 25 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04884776 (Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic), which is not on this map. Cited by 192 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed, 16 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04884776 naunknown statusnot on this map

Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic

TypeinterventionalSponsorChinese University of Hong KongRan2021 to 2024Enrolled453ConditionsGut Microbiota, COVID-19 VaccineArmsMicrobiome immunity formula, Active placebo
3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 16 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Fit4Surgery for cancer patients during covid-19 lockdown - A systematic review and meta-analysis.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes.Translational research : the journal of laboratory and clinical medicine · 2022
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Guideline
  17. Trial
  18. Trial
  19. Review
  20. Article

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

Stuart J McGurnaghanHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Amanda WeirHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Jen BishopHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Sharon KennedyHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Luke A K BlackbournInstitute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
David A McAllisterInstitute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Sharon HutchinsonSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Thomas M CaparrottaInstitute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Joseph MellorUsher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Anita JeyamInstitute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Joseph E O'ReillyInstitute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Sarah H WildUsher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Sara HatamInstitute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Andreas HöhnInstitute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Marco ColomboInstitute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Chris RobertsonHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
Nazir LoneUsher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Janet MurrayHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Elaine ButterlyInstitute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
John PetrieInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Brian KennonQueen Elizabeth University Hospital, Glasgow, UK.
Rory McCrimmonUniversity of Dundee, Dundee, UK.
Robert LindsayInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Ewan PearsonUniversity of Dundee, Dundee, UK.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
John McKnightWestern General Hospital, National Health Service Lothian Edinburgh, UK.
Sam PhilipGrampian Diabetes Research Unit, Diabetes Centre, Aberdeen Royal Infirmary, Aberdeen, UK.
Andrew CollierSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Jim McMenaminHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Alison Smith-PalmerHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
David GoldbergHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Paul M McKeigueHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Helen M ColhounHealth Protection Scotland, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Department of Public Health, National Health Service Fife, Kirkcaldy, UK. Electronic address: helen.colhoun@igmm.ed.ac.uk.
Public Health Scotland COVID-19 Health Protection Study Group
Scottish Diabetes Research Network Epidemiology Group

Funding

Wellcome Trust 201492/Z/16/Z
6 · The paper itself

Abstract

backgroundWe aimed to ascertain the cumulative risk of fatal or critical care unit-treated COVID-19 in people with diabetes and compare it with that of people without diabetes, and to investigate risk factors for and build a cross-validated predictive model of fatal or critical care unit-treated COVID-19 among people with diabetes.

methodsIn this cohort study, we captured the data encompassing the first wave of the pandemic in Scotland, from March 1, 2020, when the first case was identified, to July 31, 2020, when infection rates had dropped sufficiently that shielding measures were officially terminated. The participants were the total population of Scotland, including all people with diabetes who were alive 3 weeks before the start of the pandemic in Scotland (estimated Feb 7, 2020). We ascertained how many people developed fatal or critical care unit-treated COVID-19 in this period from the Electronic Communication of Surveillance in Scotland database (on virology), the RAPID database of daily hospitalisations, the Scottish Morbidity Records-01 of hospital discharges, the National Records of Scotland death registrations data, and the Scottish Intensive Care Society and Audit Group database (on critical care). Among people with fatal or critical care unit-treated COVID-19, diabetes status was ascertained by linkage to the national diabetes register, Scottish Care Information Diabetes. We compared the cumulative incidence of fatal or critical care unit-treated COVID-19 in people with and without diabetes using logistic regression. For people with diabetes, we obtained data on potential risk factors for fatal or critical care unit-treated COVID-19 from the national diabetes register and other linked health administrative databases. We tested the association of these factors with fatal or critical care unit-treated COVID-19 in people with diabetes, and constructed a prediction model using stepwise regression and 20-fold cross-validation.

findingsOf the total Scottish population on March 1, 2020 (n=5 463 300), the population with diabetes was 319 349 (5·8%), 1082 (0·3%) of whom developed fatal or critical care unit-treated COVID-19 by July 31, 2020, of whom 972 (89·8%) were aged 60 years or older. In the population without diabetes, 4081 (0·1%) of 5 143 951 people developed fatal or critical care unit-treated COVID-19. As of July 31, the overall odds ratio (OR) for diabetes, adjusted for age and sex, was 1·395 (95% CI 1·304-1·494; p<0·0001, compared with the risk in those without diabetes. The OR was 2·396 (1·815-3·163; p<0·0001) in type 1 diabetes and 1·369 (1·276-1·468; p<0·0001) in type 2 diabetes. Among people with diabetes, adjusted for age, sex, and diabetes duration and type, those who developed fatal or critical care unit-treated COVID-19 were more likely to be male, live in residential care or a more deprived area, have a COVID-19 risk condition, retinopathy, reduced renal function, or worse glycaemic control, have had a diabetic ketoacidosis or hypoglycaemia hospitalisation in the past 5 years, be on more anti-diabetic and other medication (all p<0·0001), and have been a smoker (p=0·0011). The cross-validated predictive model of fatal or critical care unit-treated COVID-19 in people with diabetes had a C-statistic of 0·85 (0·83-0·86).

interpretationOverall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history.

fundingNone.

Indexed as

Population SurveillanceAdultAgedAged, 80 and overCohort StudiesCOVID-19Critical CareDiabetes MellitusFemaleHumansMaleMiddle AgedRisk FactorsScotlandYoung Adult

Identifiers

PMID33357491
PMCPMC7832778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.